- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.11. | Gain Therapeutics GAAP EPS of -$0.15 beats by $0.01 | 1 | Seeking Alpha | ||
| 16.10. | Gain Therapeutics, Inc.: Gain Therapeutics to Attend the 2025 Maxim Growth Summit | 4 | GlobeNewswire (USA) | ||
| 14.10. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.10. | Gain Therapeutics, Inc.: Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease | 2 | GlobeNewswire (USA) | ||
| 06.10. | Gain Therapeutics meldet vorläufige Phase-1b-Daten für Parkinson-Medikament GT-02287 | 2 | Investing.com Deutsch | ||
| 06.10. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.10. | Gain Therapeutics reports positive early data from Parkinson's trial | 1 | Investing.com | ||
| GAIN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.10. | Gain Therapeutics, Inc.: Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders | 3 | GlobeNewswire (USA) | ||
| 23.09. | Gain Therapeutics, Inc.: Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025 | 2 | GlobeNewswire (USA) | ||
| 18.09. | Gain Therapeutics extends Phase 1b Parkinson's treatment study | 3 | Investing.com | ||
| 18.09. | Gain Therapeutics, Inc.: Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease | 140 | GlobeNewswire (Europe) | Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule The Phase 1b study enrolled... ► Artikel lesen | |
| 25.08. | H.C. Wainwright reiterates Buy rating on Gain Therapeutics stock at $8 price target | 2 | Investing.com | ||
| 25.08. | BTIG lowers Gain Therapeutics stock price target to $9 on biomarker data timing | 2 | Investing.com | ||
| 12.08. | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 12.08. | Gain Therapeutics GAAP EPS of -$0.19 misses by $0.02 | 1 | Seeking Alpha | ||
| 17.07. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Pricing of $7.0 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 15.07. | Gain Therapeutics stock falls after announcing public offering | 2 | Investing.com | ||
| 15.07. | Gain Therapeutics announces proposed public offering | 1 | Seeking Alpha |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,070 | +0,83 % | Qiagen auf der Jefferies-Konferenz: Wachstumskurs trotz Herausforderungen | ||
| OLEMA PHARMACEUTICALS | 19,460 | -3,62 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| NUVATION BIO | 7,160 | +49,01 % | Nuvation Bio stock initiated with Buy rating at B.Riley on strong Ibtrozi launch | ||
| NUVALENT | 107,08 | +2,72 % | Nuvalent, Inc.: Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC | In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 82,14 | +5,58 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Third Quarter 2025 Financial Results | SAN DIEGO, Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter... ► Artikel lesen | |
| BIONTECH | 88,00 | -0,62 % | JEFFERIES stuft Biontech auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Biontech mit einem Kursziel von 151 US-Dollar auf "Buy" belassen. Auf seinem Forschungs- und Entwicklungstag habe der Mainzer Antikörperspezialist... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,88 | +0,05 % | Avidity startet Programm für frühzeitigen Zugang zu DMD44-Therapie | ||
| ARCUTIS BIOTHERAPEUTICS | 27,900 | +2,27 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 42,050 | -3,24 % | Mineralys Therapeutic: Aktie gibt nach umfangreichen Insiderverkäufen nach | ||
| ADMA BIOLOGICS | 15,950 | +1,69 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,940 | +4,66 % | Cogent Biosciences, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 36,500 | +6,07 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671)... ► Artikel lesen | |
| EVOTEC | 5,162 | -0,77 % | Evotec: Meilenstein von Pharma-Giganten - Aktie sendet Lebenszeichen | Gute Nachrichten von Evotec. Der Hamburger Wirkstoffforscher ist wieder einen Schritt weiter in der Zusammenarbeit mit dem amerikanischen Pharma-Riesen Bristol Myers Squibb. Evotec erhält in diesem... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 189,82 | +3,04 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,035 | -3,00 % | Is Recursion Pharmaceuticals a Meme Stock? |
Das Unternehmen GAIN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,750 Euro und damit -3,17 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GAIN THERAPEUTICS INC finden Sie auf Wallstreet Online.